Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Filing tables
Filing exhibits
CMMB similar filings
Filing view
External links
Exhibit 13.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
I, Sigal Fattal, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 20-F of Chemomab Therapeutics Ltd. for the fiscal year ended December 31, 2023 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in such Annual Report on Form 20-F fairly presents, in all material respects, the financial condition and results of operations of Chemomab Therapeutics Ltd.
CHEMOMAB THERAPEUTICS LTD. | |
Date: March 28, 2024 | /s/ Sigal Fattal |
Sigal Fattal | |
Chief Financial Officer | |
(Principal Financial Officer) |